Results 211 to 220 of about 438,950 (335)

A point mutation at tyrosine-809 in the human colony-stimulating factor 1 receptor impairs mitogenesis without abrogating tyrosine kinase activity, association with phosphatidylinositol 3-kinase, or induction of c-fos and junB genes. [PDF]

, 1990
Martine F. Roussel, Sheila Shurtleff, James R. Downing, Charles J. Sherr   +3 more
openalex   +1 more source

TP53‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, EarlyView.
ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations (TP53mut) and present immense challenges due to inherent chemoresistance and poor outcomes.
Mithun Vinod Shah, Daniel A. Arber, Devendra K. Hiwase   +2 more
wiley   +1 more source

Correction: Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma. [PDF]

J Exp Clin Cancer Res
Wang J, Liu X, Hong Y, Wang S, Chen P, Gu A, Guo X, Zhao P.   +7 more
europepmc   +1 more source

Insulin activation of insulin receptor tyrosine kinase in intact rat adipocytes. An in vitro system to measure histone kinase activity of insulin receptors activated in vivo.

, 1986
Harald H. Klein, Gary R. Freidenberg, Michael P. Kladde, Jerrold M. Olefsky   +3 more
openalex   +1 more source

Shear-stress-induced von Willebrand factor binding to platelets causes the activation of tyrosine kinase(s) [PDF]

, 1994
Kuldeep Razdan, J. D. Hellums, Michael H. Kroll   +2 more
openalex   +1 more source

Classification of Myelodysplastic, Myeloproliferative, and Myelodysplastic/Myeloproliferative Neoplasms: The Past, Present, and Future

American Journal of Hematology, EarlyView.
ABSTRACT With the recent publication of new classification systems of hematopoietic neoplasms, understanding how recognition of disease entities has occurred over time and the subsequent development of formal disease classifications is of importance. This review focuses on the early recognition of myeloid disorders, especially chronic myeloid disorders,
Daniel A. Arber, Attilio Orazi
wiley   +1 more source

Neurotrophic Receptor Tyrosine Kinase 3 as a Prognostic Biomarker in Breast Cancer Using Bioinformatic Analysis. [PDF]

Medicina (Kaunas)
Choi J, Kim J, Jung YW, Park JH, Lee JH.
europepmc   +1 more source

Acquisition of insulin-dependent protein tyrosine kinase activity during Drosophila embryogenesis.

, 1985
Lilli Petruzzelli, Román Herrera, Renee Garcia‐Arenas, O M Rosen   +3 more
openalex   +1 more source

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives

American Journal of Hematology, EarlyView.
ABSTRACT Myelofibrosis (MF) is a myeloproliferative neoplasm that is accompanied by driver JAK2, CALR, or MPL mutations in more than 90% of cases, leading to constitutive activation of the JAK–STAT pathway. MF is a multifaceted disease characterized by trilineage myeloid proliferation with prominent megakaryocyte atypia and bone marrow fibrosis, as ...
Giuseppe G. Loscocco, Paola Guglielmelli
wiley   +1 more source

The Predictive Value of Soluble Fms-Like Tyrosine Kinase-1 for Prognosis in COVID-19 Patients. [PDF]

J Inflamm Res
Lai C, Wang Y, Shi F, Geng N, Liu Z, Pan W, Shi H, Ma Y, Liu B.   +8 more
europepmc   +1 more source